コンテンツにジャンプ
先端医療開発センター

トップページ > グループ紹介 > 免疫療法開発分野(柏) > 業績

業績

2017年

  1. Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology. in press 2017

2016年

  1. Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakwa H, Nobuoka D, Yawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget. 2016 Dec 27. doi: 10.18632/oncotarget.14271. [Epub ahead of print]
  2. Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, Kikkawa F, Nakatsura T. Efficacy of Glypican-3-derived Peptide Vaccine Therapy on the Survival of Patients with Refractory Ovarian Clear Cell Carcinoma. OncoImmunology. 5(11) ;e1238542, 2016
  3. Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y. BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Cell Mol Immunol. 2016 May 16. doi: 10.1038/cmi.2016.7. [Epub ahead of print]
  4. Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T. Hepatocellular carcinoma cell sensitivity to Vg9Vd2 T lymphocyte-mediated killing is increased by zoledronate. Int. J. Oncol. 48: 1794-1804, 2016
  5. Kitayama S, Zhang R, Liu T-Y, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, Kaneko S. Cellular adjuvant properties and direct cytotoxicity of redifferentiated Va24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Reports. 6 (2): 213-227, 2016
  6. Nakatsuka R, Iwaki R, Matsuoka Y, Sumide K, Kawamura H, Fujioka T, Sasaki Y, Uemura Y, Asano H, Kwon A-H, Sonoda Y. Identification and characterization of Lineage-CD45-Sca-1+ VSEL phenotypic residing in adult mouse bone tissue. Stem Cells and Development. 25: 27-42, 2016.

2015年

  1. Fujinami N, Yoshikawa T, Sawada Y, Shimomura M, Iwama T, Sugai S, Kitano S, Uemura Y, Nakatsura T. Enhancement of antitumor effect by peptide vaccine therapy in combination withanti-CD4antibody: Study in a murine model. Biochemistry and Biophysics Reports. 5;482-491,2016
  2. Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology. 5(5); e1129483,2016
  3. Iwama T, Uchida T, Sawada Y, Tsuchiya N, Sugai S, Shimomura M, Yoshikawa T, Zhang R, Uemura Y, Nakatsura T. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochem. Biophys. Res. Comm. 469(1):138-43. 2016
  4. Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma, World J Gastroenterol. 21(36):10314-10326,2015(review)
  5. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma, World J Gastroenterol. 21(37):10573-10583,2015(review)
  6. Mohammad A.S, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y. Identification of Glypican-3-Derived Long Peptides Activating both CD8+ and CD4+ T-cells; Prolonged Overall Survival in Cancer Patients with Th Cell Response. OncoImmunology. 2015 Aug 31;5(1):e1062209. eCollection 2016.
  7. Sakamoto R, Rahman MM, Shimomura M, Itoh M, Nakatsura T. Time-Lapse Imaging Assay Using the Biostation CT: A Sensitive Drug-Screening Method for 3D Cell Culture. Cancer Sci. 106(6);757-765, 2015
  8. Zhang R, Liu T, Senju S, Haruta M, Hirosawa N, Suzuki M, Tatsumi M, Ueda N, Maki H, Nakatsuka R, Matsuoka Y, Sasaki Y, Tsuzuki S, Nakanishi H, Araki R, Abe M, Akatsuka Y, Sakamoto Y, Sonoda Y, Nishimura Y, Kuzushima K. Uemura Y. Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells. Cancer Immunol. Res. 3 (6): 668-677 2015
  9. Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y. Prospectively isolated human bone marrow-derived MSCs support primitive human CD34-negative hematopoietic stem cells. Stem Cells. 33 (5): 1554-1565, 2015
  10. Nakatsuka R, Matsuoka Y, Uemura Y, Sumide K, Iwaki R, Takahashi M, Fujioka T, Sasaki Y, Sonoda Y. Mouse dental pulp stem cells support human umbilical cord blood-derived hematopoietic stem/progenitor cells in vitro. Cell Transplantation. 24: 97-113, 2015

2014年

  1. Ofuji K, Saito K, Yoshikawa T, Nakatsura T. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2014 21;1:35-42. doi: 10.2147/JHC. S48517. eCollection 2014. (review)
  2. Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T. A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer. Int. J. Oncol. 46:497-504,2015 Feb
  3. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46:28-36,2015
  4. Yoshikawa T, Takahara M, Tomiyama M, Nieda M, Maekawa R, Nakatsura T. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. Int. J. Oncol. 45:1847-1856,2014
  5. Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K, Nakatsura T. Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. Oncol. Rep. 32:1772-1778,2014
  6. Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Identification of a novel HLA-A* 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncol. Rep. 32(1):33-39,2014

2013年

  1. Sawada Y, Komori H, Tsunoda Y, Shimomura M, Takahashi M, Baba H, Ito M, Saito N, Kuwano H, Endo I, Nishimura Y, Nakatsura T. Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncol. Rep. 31(3):1051-1058,2014
  2. Suzuki S, Shibata K, Kikkawa F, Nakatsura T. Significant Clinical Response of Progressive Recurrent Ovarian Clear Cell Carcinoma to Glypican-3-derived Peptide Vaccine Therapy: Two Case Reports. Hum Vacc Immunother. 10(2):338-343,2014
  3. Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M,Shirakawa H, Nobuoka D and Nakatsura T. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide. Int. J. Oncol. 43(4):1019-1026,2013
  4. Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case.  Hum Vacc Immunother. 9(6):1228-1233,2013
  5. Nobuoka D, Yoshikawa T, Fujiwara T, and Nakatsura T.  Peptide intra-tumor injection for cancer immunotherapy:Enhancement of tumor cell antigenicity is a novel and attractive strategy. Hum Vacc Immunother. 9(6):1234-1236,2013
  6. Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement of antigen-specific cancer immunotherapy. Cancer Immunol Immun. 62(4):639-652,2013
  7. Kondo S, Demachi-Okamura A, Hirosawa T, Maki H, Fujita M, Uemura Y, Akatsuka Y, Yamamoto E, Shibata K, Ino K, Kikkawa F, Kuzushima K. An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules. Hum Immunol. 74: 1103-1110, 2013
  8. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Gotoh H, Zhu D, Nakayama K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 12: 114-126, 2013

2012年

  1. Iwama T, Horie K, Yoshikawa T, Nobuoka D, Shimomura M, Sawada Y, Nakatsura T. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int. J. Oncol. 42(3):831-838,2013
  2. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T. Peptide vaccines for hepatocellular carcinoma. Hum Vacc Immunother. 9(1):210-212,2013
  3. Sawada Y, Sakai M, Yoshikawa T, Ofuji K , Nakatsura T. A glypican-3-derived peptide vaccine against hepatocellular carcinoma. OncoImmunology. 1(8):1448-1450,2012
  4. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagori T, Takahashi S, Gotoda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma : immunological evidence and potential for improving overall survival. Clin. Cancer Res. 18(13):3686-3696, 2012
  5. Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y, Kojima S, Kuzushima K. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. J. Immunother. 35: 598-606, 2012